Theriva Biologics, Inc. Goodwill, Foreign Currency Translation Gain (Loss)
Theriva Biologics, Inc. (TOVX) reported Goodwill, Foreign Currency Translation Gain (Loss) of -$106.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-03-12
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2024-09-30 was $61.00K.
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2024-06-30 was -$40.00K, a 121.28% decline year-over-year.
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2024-03-31 was -$127.00K.
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2024 was -$106.00K, a 160.57% decline from fiscal 2023.
- Theriva Biologics, Inc. goodwill, foreign currency translation gain (loss) for fiscal 2023 was $175.00K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $61.00K derived: sum of 2 quarters · filed 2026-03-12 | $21.00K derived: sum of 3 quarters · filed 2026-03-12 | -$106.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $21.00K derived: sum of 2 quarters · filed 2024-11-12 | -$106.00K 10-Q · filed 2024-11-12 | $134.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | -$40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$167.00K 10-Q · filed 2024-08-13 | $73.00K derived: sum of 3 quarters · filed 2024-08-13 | -$88.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2024-03-31 | -$127.00K 10-Q · filed 2024-05-07 | $113.00K derived: sum of 2 quarters · filed 2024-05-07 | -$48.00K derived: sum of 3 quarters · filed 2024-05-07 | $140.00K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2023-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $79.00K derived: sum of 2 quarters · filed 2024-03-25 | $267.00K derived: sum of 3 quarters · filed 2024-03-25 | $175.00K 10-K · filed 2024-03-25 | |
| 2023-09-30 | -$161.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $27.00K derived: sum of 2 quarters · filed 2023-11-13 | -$65.00K 10-Q · filed 2023-11-13 | -$863.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-06-30 | $188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $96.00K 10-Q · filed 2023-08-08 | -$702.00K derived: sum of 3 quarters · filed 2023-08-08 | -$378.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | -$92.00K 10-Q · filed 2023-05-11 | -$890.00K derived: sum of 2 quarters · filed 2023-08-08 | -$566.00K derived: sum of 3 quarters · filed 2023-08-08 | -$219.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-12-31 | -$798.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-08-08 | -$474.00K derived: sum of 2 quarters · filed 2023-08-08 | -$127.00K derived: sum of 3 quarters · filed 2023-08-08 | -$171.00K 10-Q · filed 2023-08-08 | $171.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $671.00K derived: sum of 2 quarters · filed 2022-11-10 | $627.00K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $303.00K 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | -$44.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |